Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have been given an average rating of “Buy” by the twenty-eight ratings firms that are presently covering the firm. Eleven equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $79.38.

Several brokerages have recently issued reports on GILD. Vetr cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.88 price objective for the company. in a research note on Tuesday, April 25th. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Barclays PLC reissued an “overweight” rating and set a $85.00 price objective on shares of Gilead Sciences in a research note on Wednesday, May 3rd. BMO Capital Markets reissued a “hold” rating and set a $76.00 price objective (up from $75.00) on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Finally, Stifel Nicolaus reissued a “buy” rating and set a $87.00 price objective on shares of Gilead Sciences in a research note on Monday, April 24th.

In related news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $67.18, for a total transaction of $4,926,510.94. Following the completion of the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $214,973,917.42. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction dated Thursday, March 30th. The shares were sold at an average price of $67.48, for a total transaction of $337,400.00. Following the sale, the executive vice president now directly owns 117,988 shares of the company’s stock, valued at approximately $7,961,830.24. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 88,276 shares of company stock valued at $5,932,578. Insiders own 1.40% of the company’s stock.

Several large investors have recently made changes to their positions in GILD. Hall Laurie J Trustee increased its stake in shares of Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 250 shares in the last quarter. Cable Hill Partners LLC increased its stake in shares of Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 541 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 1,400 shares in the last quarter. Lombard Odier Transatlantic Limited Partnership increased its stake in shares of Gilead Sciences by 55.6% in the third quarter. Lombard Odier Transatlantic Limited Partnership now owns 1,400 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 500 shares in the last quarter. Finally, Dubuque Bank & Trust Co. increased its stake in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 267 shares in the last quarter. 74.19% of the stock is owned by institutional investors and hedge funds.

Shares of Gilead Sciences (NASDAQ:GILD) traded down 0.16% on Friday, reaching $64.33. The company had a trading volume of 3,925,907 shares. The firm has a market capitalization of $84.06 billion, a price-to-earnings ratio of 6.80 and a beta of 1.11. The firm has a 50-day moving average price of $66.84 and a 200 day moving average price of $70.67. Gilead Sciences has a 1-year low of $63.88 and a 1-year high of $88.85.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.18 by $0.02. Gilead Sciences had a net margin of 44.43% and a return on equity of 92.36%. The company had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.66 billion. Equities research analysts predict that Gilead Sciences will post $8.21 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 29th. Investors of record on Friday, June 16th will be given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 3.23%. The ex-dividend date of this dividend is Wednesday, June 14th. Gilead Sciences’s dividend payout ratio is presently 18.91%.

ILLEGAL ACTIVITY WARNING: “Gilead Sciences, Inc. (GILD) Given Average Rating of “Buy” by Analysts” was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/05/19/gilead-sciences-inc-gild-given-average-rating-of-buy-by-analysts.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

5 Day Chart for NASDAQ:GILD

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.